B. W. Robinson, A. W. Musk, and R. A. Lake, Malignant mesothelioma, Lancet, vol.366, pp.397-408, 2005.

A. Scherpereel, P. Astoul, and P. Baas, Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma, Eur Respir J, vol.35, pp.479-495, 2010.

M. Gregoire, What's the place of immunotherapy in malignant mesothelioma treatments?, Cell Adh Migr, vol.4, pp.153-161, 2010.

B. W. Robinson, C. Robinson, and R. A. Lake, Localised spontaneous regression in mesothelioma -possible immunological mechanism, Lung Cancer, vol.32, pp.197-201, 2001.

R. A. Leigh and I. Webster, Lymphocytic infiltration of pleural mesothelioma and its significance for survival, Afr Med J, vol.61, pp.1007-1009, 1982.

M. Anraku, K. S. Cunningham, and Z. Yun, Impact of tumourinfiltrating T cells on survival in patients with malignant pleural mesothelioma, J Thorac Cardiovasc Surg, vol.135, pp.823-829, 2008.

N. Yamada, S. Oizumi, and E. Kikuchi, CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection, Cancer Immunol Immunother, vol.59, pp.1543-1549, 2010.

M. Gregoire, C. Ligeza-poisson, and N. Juge-morineau, Anti-cancer therapy using dendritic cells and apoptotic tumour cells: preclinical data in human mesothelioma and acute myeloid leukaemia, Vaccine, vol.21, pp.791-794, 2003.

F. Ebstein, C. Sapede, and P. J. Royer, Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells, Am J Respir Crit Care Med, vol.169, pp.1322-1330, 2004.

J. P. Hegmans, J. D. Veltman, and M. E. Lambers, Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma, Am J Respir Crit Care Med, vol.181, pp.1383-1390, 2010.

J. Yokokawa, C. Palena, and P. Arlen, Identification of novel human CTL epitopes and their agonist epitopes of mesothelin, Clin Cancer Res, vol.11, pp.6342-6351, 2005.

R. J. May, T. Dao, and J. Pinilla-ibarz, Peptide epitopes from the Wilms' tumour 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumour cells, Clin Cancer Res, vol.13, pp.4547-4555, 2007.

A. M. Vlad, J. C. Kettel, and N. M. Alajez, MUC1 immunobiology: from discovery to clinical applications, Adv Immunol, vol.82, pp.249-293, 2004.

R. E. Beatson, J. Taylor-papadimitriou, and J. M. Burchell, MUC1 immunotherapy, Immunotherapy, vol.2, pp.305-327, 2010.

D. L. Barnd, M. S. Lan, and R. S. Metzgar, Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by human cytotoxic T cells, Proc Natl Acad Sci, vol.86, pp.7159-7163, 1989.

H. Noto, T. Takahashi, and Y. Makiguchi, Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin, Int Immunol, vol.9, pp.791-798, 1997.

Y. Hinoda, T. Takahashi, and T. Hayashi, Enhancement of reactivity of anti-MUC1 core protein antibody and killing activity of anti-MUC1 cytotoxic T cells by deglycosylation of target tissues or cells, J Gastroenterol, vol.33, pp.164-171, 1998.

S. B. Ho, G. A. Niehans, and C. Lyftogt, Heterogeneity of mucin gene expression in normal and neoplastic tissues, Cancer Res, vol.53, pp.641-651, 1993.

E. M. Hiltbold, M. D. Alter, and P. Ciborowski, Presentation of MUC1 tumour antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells, Cell Immunol, vol.194, pp.143-149, 1999.

P. Brossart, K. S. Heinrich, and G. Stuhler, Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumour antigen for broadly applicable vaccine therapies, Blood, vol.93, pp.4309-4317, 1999.

P. Brossart, A. Schneider, and P. Dill, The epithelial tumour antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes, Cancer Res, vol.61, pp.6846-6850, 2001.

K. Y. Tsang, C. Palena, and J. Gulley, A human cytotoxic Tlymphocyte epitope and its agonist epitope from the nonvariable number of tandem repeat sequence of MUC-1, Clin Cancer Res, vol.10, pp.2139-2149, 2004.

J. Creaney, A. Segal, and G. Sterrett, Overexpression and altered glycosylation of MUC1 in malignant mesothelioma, Br J Cancer, vol.98, pp.1562-1569, 2008.

F. Gueugnon, S. Leclercq, and C. Blanquart, Identification of novel markers for the diagnosis of malignant pleural mesothelioma, Am J Pathol, vol.178, pp.1033-1042, 2011.

R. D. Salter and P. Cresswell, Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid, EMBO J, vol.5, pp.943-949, 1986.

J. F. Fonteneau, M. Larsson, and S. Somersan, Generation of high quantities of viral and tumour-specific human CD4+ and CD8+ Tcell clones using peptide pulsed mature dendritic cells, J Immunol Methods, vol.258, pp.111-126, 2001.

F. Davodeau, M. Difilippantonio, and E. Roldan, The tight interallelic positional coincidence that distinguishes T-cell receptor Ja usage does not result from homologous chromosomal pairing during VaJa rearrangement, EMBO J, vol.20, pp.4717-4729, 2001.

B. Arden, S. P. Clark, and D. Kabelitz, Human T-cell receptor variable gene segment families, Immunogenetics, vol.42, pp.455-500, 1995.

Y. Cao and U. Karsten, Binding patterns of 51 monoclonal antibodies to peptide and carbohydrate epitopes of the epithelial mucin (MUC1) on tissue sections of adenolymphomas of the parotid (Warthin's tumours): role of epitope masking by glycans, Histochem Cell Biol, vol.115, pp.349-356, 2001.

A. Thathiah and D. D. Carson, MT1-MMP mediates MUC1 shedding independent of TACE/ADAM17, Biochem J, vol.382, pp.363-373, 2004.

A. Thathiah, C. P. Blobel, and D. D. Carson, Tumour necrosis factor-a converting enzyme/ADAM 17 mediates MUC1 shedding, J Biol Chem, vol.278, pp.3386-3394, 2003.

M. Odaka, D. H. Sterman, and R. Wiewrodt, Eradication of intraperitoneal and distant tumour by adenovirus-mediated interferon-b gene therapy is attributable to induction of systemic immunity, Cancer Res, vol.61, pp.6201-6212, 2001.

D. H. Sterman, A. Recio, and R. G. Carroll, A phase I clinical trial of single-dose intrapleural IFN-b gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumour immune responses, Clin Cancer Res, vol.13, pp.4456-4466, 2007.

G. Ali, L. Boldrini, and M. Lucchi, Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact, Br J Cancer, vol.101, pp.1869-1875, 2009.

P. Astoul, D. Picat-joossen, and J. R. Viallat, Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study, Cancer, vol.83, pp.2099-2104, 1998.

B. Castagneto, S. Zai, and L. Mutti, Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: results of a phase II study on 31 consecutive patients, Lung Cancer, vol.31, pp.303-310, 2001.

P. L. Friedlander, C. L. Delaune, and J. M. Abadie, Efficacy of CD40 ligand gene therapy in malignant mesothelioma, Am J Respir Cell Mol Biol, vol.29, pp.321-330, 2003.

R. H. Vonderheide, K. T. Flaherty, and M. Khalil, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody, J Clin Oncol, vol.25, pp.876-883, 2007.

V. Apostolopoulos, G. A. Pietersz, and A. Tsibanis, Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1, Breast Cancer Res, vol.8, p.27, 2006.

R. Dreicer, W. M. Stadler, and F. R. Ahmann, MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure, Invest New Drugs, vol.27, pp.379-386, 2009.

B. E. Loveland, A. Zhao, and S. White, Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma, Clin Cancer Res, vol.12, pp.869-877, 2006.

S. A. North, K. Graham, and D. Bodnar, A pilot study of the liposomal MUC1 vaccine BLP25 in prostate specific antigen failures after radical prostatectomy, J Urol, vol.176, pp.91-95, 2006.

R. Ramlau, E. Quoix, and J. Rolski, A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer, J Thorac Oncol, vol.3, pp.735-744, 2008.